Chinese biotech firm Ascletis raises $400 million in HK IPO, say sources: Reuters

Chinese biotech Ascletis Pharma Inc (1672.HK) raised $400 million after pricing its IPO in the middle of an indicative range, sources told Reuters, in the first such Hong Kong listing under rules designed to attract early-stage biotech firms.